Celestia S Higano

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi request reprint Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
    Eric J Small
    UCSF Comprehensive Cancer Center, University of California, San Francisco, 1600 Divisadero St, Box 1711, San Francisco, CA 94115, USA
    J Clin Oncol 24:3089-94. 2006
  2. doi request reprint Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
    Celestia S Higano
    Department of Oncology and Urology, University of Washington, Seattle, WA, USA
    Cancer 115:3670-9. 2009
  3. doi request reprint New and emerging agents for the treatment of castration-resistant prostate cancer
    Celestia S Higano
    Department of Medicine, University of Washington School of Medicine, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Urol Oncol 29:S1-8. 2011
  4. doi request reprint Sexuality and intimacy after definitive treatment and subsequent androgen deprivation therapy for prostate cancer
    Celestia S Higano
    FACP, Seattle Cancer Care Alliance, Seattle, WA 98109 1023, USA
    J Clin Oncol 30:3720-5. 2012
  5. doi request reprint New treatment options for patients with metastatic castration-resistant prostate cancer
    Celestia S Higano
    University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Cancer Treat Rev 38:340-5. 2012
  6. pmc Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer
    Evan Y Yu
    University of Washington Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Clin Oncol 30:1864-70. 2012
  7. ncbi request reprint Bone loss and the evolving role of bisphosphonate therapy in prostate cancer
    Celestia S Higano
    Departments of Medicine and Urology, University of Washington School of Medicine, Seattle, WA 98109, USA
    Urol Oncol 21:392-8. 2003
  8. ncbi request reprint Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?
    Celestia S Higano
    University of Washington, Seattle Cancer Care Alliance, Seattle, WA 98109, USA
    Nat Clin Pract Urol 5:24-34. 2008
  9. ncbi request reprint Safety analysis of repeated high doses of samarium-153 lexidronam in men with hormone-naive prostate cancer metastatic to bone
    Celestia S Higano
    Medicine and Urology, University of Washington Medical Center, Division of Medical Oncology, Seattle, WA 98109, USA
    Clin Genitourin Cancer 6:40-5. 2008
  10. ncbi request reprint Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician
    Celestia S Higano
    Department of Medicine and Department of Urology, University of Washington, 825 Eastlake Avenue East, Mail Stop G3 200, Seattle, WA 98109, USA
    Urol Clin North Am 31:331-52. 2004

Detail Information

Publications63

  1. ncbi request reprint Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
    Eric J Small
    UCSF Comprehensive Cancer Center, University of California, San Francisco, 1600 Divisadero St, Box 1711, San Francisco, CA 94115, USA
    J Clin Oncol 24:3089-94. 2006
    ..A phase III study was undertaken to evaluate the safety and efficacy of sipuleucel-T in a placebo-controlled study...
  2. doi request reprint Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
    Celestia S Higano
    Department of Oncology and Urology, University of Washington, Seattle, WA, USA
    Cancer 115:3670-9. 2009
    ..The safety and efficacy of sipuleucel-T was evaluated in 2 identically designed, randomized, double-blind, placebo-controlled trials (D9901 and D9902A) conducted in men with advanced prostate cancer...
  3. doi request reprint New and emerging agents for the treatment of castration-resistant prostate cancer
    Celestia S Higano
    Department of Medicine, University of Washington School of Medicine, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Urol Oncol 29:S1-8. 2011
    ..These realities make clinical trial design more challenging than ever...
  4. doi request reprint Sexuality and intimacy after definitive treatment and subsequent androgen deprivation therapy for prostate cancer
    Celestia S Higano
    FACP, Seattle Cancer Care Alliance, Seattle, WA 98109 1023, USA
    J Clin Oncol 30:3720-5. 2012
    ..Suggestions for clinicians to better help patients and their partners regarding sexuality and intimacy are offered...
  5. doi request reprint New treatment options for patients with metastatic castration-resistant prostate cancer
    Celestia S Higano
    University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Cancer Treat Rev 38:340-5. 2012
    ....
  6. pmc Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer
    Evan Y Yu
    University of Washington Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Clin Oncol 30:1864-70. 2012
    ..To investigate changes in bone mineral density (BMD) and fracture risk in men who received intermittent androgen deprivation (IAD) for nonmetastatic, hormone-sensitive prostate cancer...
  7. ncbi request reprint Bone loss and the evolving role of bisphosphonate therapy in prostate cancer
    Celestia S Higano
    Departments of Medicine and Urology, University of Washington School of Medicine, Seattle, WA 98109, USA
    Urol Oncol 21:392-8. 2003
    ..Whether zoledronic acid or other bisphosphonates might actually prevent or delay the development of bone metastases remains to be studied in randomized clinical trials...
  8. ncbi request reprint Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?
    Celestia S Higano
    University of Washington, Seattle Cancer Care Alliance, Seattle, WA 98109, USA
    Nat Clin Pract Urol 5:24-34. 2008
    ..Future studies should address the long-term impact of antiresorptive therapy on actual fracture rate and the impact on quality of life and healthcare costs...
  9. ncbi request reprint Safety analysis of repeated high doses of samarium-153 lexidronam in men with hormone-naive prostate cancer metastatic to bone
    Celestia S Higano
    Medicine and Urology, University of Washington Medical Center, Division of Medical Oncology, Seattle, WA 98109, USA
    Clin Genitourin Cancer 6:40-5. 2008
    ..The safety and tolerability of repetitive doses of the boneseeking radiopharmaceutical samarium-153 lexidronam (153Sm- EDTMP) were investigated in men with hormone-naive prostate cancer metastatic to bone...
  10. ncbi request reprint Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician
    Celestia S Higano
    Department of Medicine and Department of Urology, University of Washington, 825 Eastlake Avenue East, Mail Stop G3 200, Seattle, WA 98109, USA
    Urol Clin North Am 31:331-52. 2004
    ..Continuing trials may give us guidance in the future...
  11. ncbi request reprint Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancer
    Celestia S Higano
    University of Washington Medical Center, Seattle, Washington 98109, USA
    Clin Cancer Res 10:1219-25. 2004
    ....
  12. ncbi request reprint Management of bone loss in men with prostate cancer
    Celestia S Higano
    Seattle Cancer Care Alliance, University of Washington, 98109, USA
    J Urol 170:S59-63; discussion S64. 2003
    ..Skeletal metabolism and osteoporosis in men, assessment of bone mineral density (BMD), effects of ADT on BMD, management strategies and potential therapies for osteopenia or osteoporosis in men with prostate cancer are reviewed...
  13. pmc Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation
    Evan Y Yu
    Department of Medicine, Division of Oncology, University of Washington, 825 Eastlake Ave E, Seattle, WA 98109, USA
    J Clin Oncol 28:2668-73. 2010
    ....
  14. pmc Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University of Washington Rapid Autopsy Series
    Colm Morrissey
    Department of Urology, University of Washington, Seattle, WA 98195, USA
    J Bone Miner Res 28:333-40. 2013
    ..Furthermore, in this cohort of patients, BP treatment increased BV and did not decrease the number of osteoclasts in prostate cancer bone metastases compared with bone metastases from patients who did not receive BP...
  15. pmc Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth
    R Bruce Montgomery
    Department of Medicine, University of Washington School of Medicine, Weattle, WA, USA
    Cancer Res 68:4447-54. 2008
    ..Maximal therapeutic efficacy in the treatment of castration-resistant prostate cancer will require novel agents capable of inhibiting intracrine steroidogenic pathways within the prostate tumor microenvironment...
  16. ncbi request reprint Metastases of prostate cancer express estrogen receptor-beta
    Janice S Lai
    Department of Urology, University of Washington School of Medicine, Seattle, Washington 98195, USA
    Urology 64:814-20. 2004
    ..It has been proposed that ERbeta may play a role in the growth regulation of prostate cells. The targeting of ERs by selective ER modulators might be an effective method of treating advanced CaP...
  17. pmc Histopathological assessment of prostate cancer bone osteoblastic metastases
    Martine P Roudier
    Department of Pathology, University of Washington and Research Service, Seattle, Washington, USA
    J Urol 180:1154-60. 2008
    ..The discrepancy between the radiological and clinical aspects of those events is not well understood. We better characterized the histopathology of bone processes in prostate cancer bone metastases...
  18. ncbi request reprint Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators
    Tomasz M Beer
    Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
    J Clin Oncol 25:669-74. 2007
    ..To compare the safety and activity of DN-101, a new high-dose oral formulation of calcitriol designed for cancer therapy, and docetaxel with placebo and docetaxel...
  19. ncbi request reprint Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel
    Tomasz M Beer
    Department of Medicine, Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
    Invest New Drugs 25:565-70. 2007
    ..6%). One subject (2.6%) had a grade 4 treatment peripheral motor neuropathy. Further study of this dose and schedule of KOS-862 in this patient population cannot be recommended due to both lack of activity and excessive toxicity...
  20. ncbi request reprint Expression of the human cachexia-associated protein (HCAP) in prostate cancer and in a prostate cancer animal model of cachexia
    Zejing Wang
    Department of Urology, University of Washington, Seattle, WA 98195, USA
    Int J Cancer 105:123-9. 2003
    ..Our results demonstrated that human CaP cells express HCAP and the expression of HCAP is associated with the progression of CaP and the development of CaP cachexia...
  21. ncbi request reprint Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases
    Colm Morrissey
    Genitourinary Cancer Research Laboratory, Department of Urology, University of Washington, Seattle, WA 98195, USA
    Clin Exp Metastasis 25:377-88. 2008
    ..In addition, the resulting tumor-associated microvessel density and distribution was significantly different between liver and bone metastasis possibly in response to the protein expression changes detailed above...
  22. ncbi request reprint Current status of treatment for patients with metastatic prostate cancer
    Celestia S Higano
    Seattle Cancer Care Alliance, University of Washington, Seattle, WA 98109, USA
    Can J Urol 12:38-41. 2005
    ..Additional adjunctive therapy with the bisphosphonate, zoledronic acid, to reduce skeletal complications should be considered...
  23. pmc Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases
    Canan Akfirat
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Pathol 230:291-7. 2013
    ..Altogether, this suggests that optimal therapeutic inhibition may require combinations of drugs that target both bone and soft tissue-specific survival pathways...
  24. pmc Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases
    Sandy R Larson
    Department of Urology, University of Washington, Seattle, Washington 98195, USA
    Prostate 73:932-40. 2013
    ..We determined whether previously identified and/or novel proteins were associated with the osteoblastic or osteolytic response in clinical specimens of PCa bone metastases...
  25. pmc Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346)
    Catherine M Tangen
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    J Urol 188:1164-9. 2012
    ..We also assessed whether any patient subsets benefited differentially during this period...
  26. ncbi request reprint Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone
    Martine P Roudier
    Department of Urology, University of Washington, and Puget Sound VA Medical Center, Seattle, 98195, USA
    Hum Pathol 34:646-53. 2003
    ..Consequently, therapy directed to the phenotype of 1 metastasis may have no effect on other metastases in the same patient because of phenotypic heterogeneity...
  27. pmc Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer
    Amir Goldkorn
    Amir Goldkorn, David I Quinn, and Tong Xu, University of Southern California Keck School of Medicine and Norris Comprehensive Cancer Center, Los Angeles Przemyslaw Twardowski, City of Hope, Duarte Philip C Mack and Primo Lara Jr, University of California, Davis, Sacramento, CA Benjamin Ely and Catherine M Tangen, Southwest Oncology Group Statistical Center Celestia S Higano, Puget Sound Oncology Consortium, Seattle Cancer Care Alliance, and University of Washington, Seattle, WA Louis M Fink, Nevada Cancer Institute Nicholas J Vogelzang, Comprehensive Cancer Centers of Nevada and US Oncology Research, Las Vegas, NV Peter J Van Veldhuizen, University of Kansas Cancer Center, Westwood, KS Neeraj Agarwal, University of Utah Huntsman Cancer Institute, Salt Lake City, UT Michael A Carducci, Johns Hopkins Kimmel Cancer Center and Eastern Cooperative Oncology Group, Baltimore, MD J Paul Monk III, Ohio State University and Cancer and Leukemia Group B, Columbus, OH Ram H Datar and Richard J Cote, University of Miami Miller School of Medicine, Miami, FL Mark Garzotto, Portland Veterans Affairs Medical Center, Portland, Kitakobayashi 880
    J Clin Oncol 32:1136-42. 2014
    ..We assessed the prognostic value of CTCs for overall survival (OS) and disease response in S0421, a phase III trial of docetaxel plus prednisone with or without atrasentan...
  28. ncbi request reprint Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15
    Chung Ying Huang
    Division of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98105 1024, USA
    Clin Cancer Res 13:5825-33. 2007
    ..To identify molecular alterations associating with in vivo exposure of prostate carcinoma to chemotherapy and assess functional roles modulating tumor response and resistance...
  29. pmc Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer
    Evan Y Yu
    University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    J Urol 188:103-9. 2012
    ..We investigated this screening failure rate to promote better classification of patients thought to have nonmetastatic castration resistant prostate cancer and inform the design of future clinical trials in this setting...
  30. doi request reprint Positive surgical margins: the argument for androgen deprivation and chemotherapy
    Celestia S Higano
    Department of Urology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA 98109, USA
    Urol Oncol 27:89-91. 2009
    ....
  31. pmc Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet 375:1437-46. 2010
    ..Because growth of castration-resistant prostate cancer is dependent on continued androgen-receptor signalling, we assessed the antitumour activity and safety of MDV3100 in men with this disease...
  32. ncbi request reprint Darbepoetin alfa administered every 4 weeks for anemia in patients with advanced prostate cancer
    Tomasz M Beer
    Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239, USA
    Clin Genitourin Cancer 5:329-33. 2007
    ..We sought to determine if infrequent dosing of darbepoetin alfa is safe and effective in treating anemia in patients receiving systemic therapy for prostate cancer...
  33. pmc Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer
    Ilona N Holcomb
    Divisions of Human Biology, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington, USA
    Cancer Res 69:7793-802. 2009
    ..Our investigation lays the foundation for a better understanding of and possible therapeutic targets for CR disease, the poorly responsive and final stage of prostate cancer...
  34. ncbi request reprint Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer
    Celestia S Higano
    Department of Oncology, University of Washington Seattle, Seattle, Washington, USA
    Cancer 113:975-84. 2008
    ..The immunotherapy, based on the GVAX platform, consisted of 2 allogeneic prostate-carcinoma cell lines modified to secrete granulocyte-macrophage-colony-stimulating factor (GM-CSF)...
  35. ncbi request reprint To treat or not to treat, that is the question: the role of bone-targeted therapy in metastatic prostate cancer
    Celestia S Higano
    University of Washington, Seattle, WA
    J Clin Oncol 32:1107-11. 2014
    ..A prostate biopsy revealed Gleason 4+4 adenocarcinoma of the prostate. Androgen deprivation therapy with leuprolide acetate was initiated, and the addition of a bone-targeted agent was considered. ..
  36. pmc A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors
    Xiaoyu Qu
    Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
    PLoS ONE 8:e74671. 2013
    ..64, P<0.001). Overall, the three-marker FISH panel may represent a useful tool for risk stratification of prostate cancer patients. ..
  37. doi request reprint Enzalutamide, a second generation androgen receptor antagonist: development and clinical applications in prostate cancer
    Manoj P Menon
    University of Washington and Fred Hutchinson Cancer Research Center, c o Seattle Cancer Care Alliance, Seattle, WA 98109, USA
    Curr Oncol Rep 15:69-75. 2013
    ..Some of the new challenges confronting the field regarding sequencing and combinations of these agents and the potential for a change in the natural history of the disease, are also discussed...
  38. ncbi request reprint Side effects of androgen deprivation therapy: monitoring and minimizing toxicity
    Celestia S Higano
    Department of Urology, University of Washington School of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, Washington 98109, USA
    Urology 61:32-8. 2003
    ..These side effects need more systematic study in clinical trials. Physicians should be aware of far-reaching consequences of ADT and should incorporate strategies for preventing and managing toxicities into routine practice...
  39. ncbi request reprint Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer
    Eva Corey
    Department of Urology, University of Washington, Seattle, Washington 98195, USA
    Clin Cancer Res 9:295-306. 2003
    ..In this study we have examined the effects of zoledronic acid (ZA), a new-generation bisphosphonate, on prostate cancer (CaP) cells in vitro, and on both osteoblastic and osteolytic CaP metastases in animal models...
  40. doi request reprint The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer
    Oliver Sartor
    Department of Medicine, Tulane University, New Orleans, Louisiana 70115, USA
    Urology 75:623-9. 2010
    ..This article describes the design of the COMPARE Registry, together with patient characteristics and prostate cancer management at enrolment...
  41. pmc Changes in neuronal activation patterns in response to androgen deprivation therapy: a pilot study
    Monique M Cherrier
    Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA 98195, USA
    BMC Cancer 10:1. 2010
    ..A common treatment option for men with prostate cancer is androgen deprivation therapy (ADT). However, men undergoing ADT may experience physical side effects, changes in quality of life and sometimes psychiatric and cognitive side effects...
  42. ncbi request reprint Intermittent androgen deprivation: clinical experience and practical applications
    Jonathan L Wright
    Department of Urology, University of Washington, Seattle, WA 98195, USA
    Urol Clin North Am 33:167-79, vi. 2006
    ..This article discusses the theoretical benefits and rationale of IAD and reviews the completed and on-going IAD trials. Finally, the controversies, practical applications, and future directions of IAD are addressed...
  43. pmc C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy
    Evan Y Yu
    Division of Oncology, Department of Medicine, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Clin Nucl Med 36:192-8. 2011
    ....
  44. ncbi request reprint Does chemotherapy have a role before hormone-resistant disease develops?
    James P Dean
    Department of Medicine, Division of Medical Oncology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA 98109, USA
    Curr Urol Rep 10:226-35. 2009
    ..This review discusses the status of chemotherapy in prostate cancer and addresses evidence regarding the use of chemotherapy in hormone-sensitive disease, alone and in combination with androgen deprivation therapy...
  45. ncbi request reprint Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733
    Celestia S Higano
    Department of Medicine, Division of Oncology, University of Washington, Seattle, Washington, USA
    Cancer 112:2181-7. 2008
    ..Many patients with invasive urothelial cell cancer are poor candidates for cisplatin-based chemotherapy, and many are high risk for cystectomy. Southwest Oncology Group Trial 8733 was designed to address treatment for such patients...
  46. doi request reprint PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine
    Martin A Cheever
    Clinical Research Division, Fred Hutchinson Cancer Research Center, and Division of Medical Oncology, University of Washington, Seattle, WA 98109, USA
    Clin Cancer Res 17:3520-6. 2011
    ..The preclinical and clinical development of sipuleucel-T is reviewed, and approaches to enhance efficacy are considered herein...
  47. ncbi request reprint Elevation of cytokine levels in cachectic patients with prostate carcinoma
    Jesco Pfitzenmaier
    Department of Urology, University of Washington, Seattle, Washington 98195, USA
    Cancer 97:1211-6. 2003
    ..The objective of the current study was to determine whether cachexia associated with advanced CaP is accompanied by increased serum levels of TNFalpha, IL-1beta, IL-6, and IL-8...
  48. pmc Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells
    James D Lord
    Department of Medicine, University of Washington, Seattle, WA, USA
    Dig Dis Sci 55:1396-405. 2010
    ..However, we found no evidence of FOXP3(+) T cell depletion in any of the nine patients who developed colitis...
  49. pmc Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer
    Christine M Barnett
    Authors Affiliations Knight Cancer Institute Department of Public Health and Preventive Medicine Knight Diagnostic Laboratories, Oregon Health and Science University Portland VA Medical Center, Portland, Oregon and Puget Sound Oncology Consortium, Seattle Cancer Care Alliance, University of Washington, Seattle, Washington
    Clin Cancer Res 20:1306-12. 2014
    ..We examined the prevalence of potentially therapeutically actionable mutations in patients with high-risk clinically localized prostate cancer...
  50. ncbi request reprint Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment
    Peter R Carroll
    Department of Urology, University of California School of Medicine, San Francisco 94115 1711, USA
    J Urol 170:S3-5. 2003
  51. ncbi request reprint Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies
    Terrence H Diamond
    Department of Medicine, University of New South Wales, St George Hospital Campus, Sydney, Australia
    Cancer 100:892-9. 2004
    ..In the current review, the authors addressed the current research, diagnostic methods, and treatment recommendations for bone loss and osteoporosis in men with prostate carcinoma who received ADT...
  52. ncbi request reprint Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer
    Matthew R Smith
    Massachusetts General Hospital, Cox 640, 100 Blossom St, Boston, MA 02114, USA
    J Clin Oncol 23:2918-25. 2005
    ..To describe the natural history of nonmetastatic prostate cancer and rising prostate-specific antigen (PSA) despite androgen deprivation therapy...
  53. ncbi request reprint The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel
    Fred Saad
    Universite de Montreal, Quebec, Canada
    Clin Genitourin Cancer 4:257-62. 2006
    ..However, further study of the use of bisphosphonates across the clinical spectrum of prostate cancer is needed...
  54. ncbi request reprint Guideline for the management of clinically localized prostate cancer: 2007 update
    Ian Thompson
    American Urological Association Education and Research, Inc
    J Urol 177:2106-31. 2007
  55. ncbi request reprint Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the re
    Michael S Cookson
    Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    J Urol 177:540-5. 2007
    ....
  56. ncbi request reprint Annual zoledronic acid: is less more?
    Celestia S Higano
    J Clin Oncol 25:1026. 2007
  57. pmc Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer
    James L Gulley
    Center for Cancer Research, Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland 20892, USA
    J Urol 180:1432-7; discussion 1437. 2008
    ..To our knowledge this represents the largest study using monthly testosterone and dihydroxytestosterone measurement to evaluate the kinetics of androgen recovery following limited androgen deprivation therapy...
  58. ncbi request reprint American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer
    Ethan M Basch
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 25:5313-8. 2007
    ..The review panel notes that CCO has published separate guidelines on radiopharmaceuticals and bisphosphonates in men with castration-resistant (ie, hormone-refractory) metastatic prostate cancer...
  59. ncbi request reprint Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer
    Tomasz M Beer
    Divisions of Hematology and Medical Oncology, Oregon Health Sciences University and Portland Veterans Affairs Medical Center, Portland, Oregon 97239, USA
    Clin Cancer Res 10:1306-11. 2004
    ..The purpose is to determine the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of mitoxantrone and docetaxel administered weekly before prostatectomy in men with localized prostate cancer at high risk for recurrence...
  60. ncbi request reprint Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer
    Mark Garzotto
    Urology Section, Surgical Service, Portland VA Medical Center, Portland, OR 97239, USA
    Urol Oncol 24:254-9. 2006
    ..The goal of this phase I/II study is to evaluate the safety and efficacy of neoadjuvant docetaxel and mitoxantrone before prostatectomy...
  61. ncbi request reprint A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapy
    James L Gulley
    Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Urol 173:1567-71. 2005
    ..We present the largest published series of patients evaluating the timing of T and DHT increase after cessation of GnRH therapy...
  62. ncbi request reprint Erectile function outcome reporting after clinically localized prostate cancer treatment
    Arthur L Burnett
    The Johns Hopkins Hospital, 600 North Wolfe St, Marburg 407, Baltimore, Maryland 21287 2411, USA
    J Urol 178:597-601. 2007
    ....